GenScript Receives 'AA' MSCI Sustainability Score for Environmental, Social, and Governance Practices
GenScript Biotech Achieves AA MSCI ESG Rating, Reinforcing Commitment to Sustainability
GenScript Biotech Corporation, a leading player in the biotech industry, has earned an upgraded AA MSCI ESG rating, reflecting excellence in product safety, human capital development, environmental, and governance practices. This achievement underscores the company's strong commitment to sustainability and its mission to 'Make People and Nature Healthier through Biotechnology.'
The MSCI ESG Ratings are a widely used benchmark for global capital markets, evaluating companies on a scale from CCC to AAA. GenScript's AA rating signifies the company as a global ESG leader in the biotech industry.
In addition to the MSCI recognition, GenScript has also achieved a Silver Medal from EcoVadis, ranking it in the top 15% globally for sustainability. The company has also received a "Low Risk" ESG rating from Morningstar Sustainalytics.
GenScript's commitment to sustainability is not limited to these achievements. The company is a participant of the United Nations Global Compact (UNGC), adhering to its ten universal principles on human rights, labor, environment, and anti-corruption. GenScript is also a supplier partner of the Pharmaceutical Supply Chain Initiative (PSCI), driving sustainable practices in the pharmaceutical industry's value chains.
One of the tangible actions taken by GenScript to promote environmental sustainability is the upgrading of its product packaging through a recyclable strategy. This move has resulted in a significant reduction of packaging waste, with a cut of 82%.
Sherry Shao, Rotating CEO of GenScript Biotech, stated that the AA rating is a testament to the company's ESG performance. "We are committed to embedding sustainability into our core business strategies, enhancing operational resilience, creating long-term value for investors and stakeholders worldwide," she said.
GenScript's inclusion in the FTSE4Good Index Series further highlights the company's strong commitment to sustainability. The validation by the Science Based Targets initiative (SBTi) demonstrates GenScript's strong commitment and actions toward combating climate change.
For more information about GenScript Biotech and its sustainability initiatives, visit https://www.genscript.com.
[1] GenScript Biotech Achieves AA MSCI ESG Rating, Reinforcing Commitment to Sustainability. (n.d.). Retrieved April 25, 2022, from https://www.genscript.com [2] GenScript Biotech Corporation. (n.d.). Retrieved April 25, 2022, from https://www.genscript.com [3] MSCI ESG Ratings. (n.d.). Retrieved April 25, 2022, from https://www.msci.com/esg-climate-risk [4] United Nations Global Compact. (n.d.). Retrieved April 25, 2022, from https://www.unglobalcompact.org
- GenScript Biotech's AA MSCI ESG rating demonstrates its leadership and dedication in the sphere of education-and-self-development, particularly human capital development, within technology and science, as well as its commitment to sustainability.
- The company's numerous awards, such as the EcoVadis Silver Medal, Morningstar Sustainalytics' "Low Risk" ESG rating, and inclusion in the FTSE4Good Index Series, showcase its significant efforts in lifestyle changes through biotechnology, while adhering to various sustainability principles and combating climate change.
